share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moore Matthew Richard

SEC announcement ·  Mar 6 17:11
Summary by Moomoo AI
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of company stock on March 4, 2024. The transaction involved the disposal of 3,468 shares of common stock at a price of $11.1212 per share, resulting in a total sale value of $38,568.32. Following the sale, Moore's direct holdings in the company amount to 146,020 shares of common stock.
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of company stock on March 4, 2024. The transaction involved the disposal of 3,468 shares of common stock at a price of $11.1212 per share, resulting in a total sale value of $38,568.32. Following the sale, Moore's direct holdings in the company amount to 146,020 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more